Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market to Surpass USD 33 Billion by 2031 Driven by Rising Global Incidence Rates

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market- (By Drug Class (Bronchodilators, Combination, Corticosteroids, Phosphodiesterase), By Type (Chronic Bronchitis, Emphysema), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market is valued at US$ 19.49 Bn in 2023, and it is expected to reach US$ 33.61 Bn by 2031, with a CAGR of 7.20% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2311

Chronic Obstructive Pulmonary Disease (COPD) encompasses a group of progressive lung disorders characterized by breathing difficulties, primarily including emphysema and chronic bronchitis. Dyspnea, or shortness of breath, remains one of the most prevalent and debilitating symptoms associated with the condition. A significant factor expected to drive growth in the COPD therapeutics market is the increasing global prevalence of the disease. Additionally, the market is anticipated to expand throughout the forecast period due to rising tobacco use among younger populations and heightened public awareness regarding the cost-effectiveness and availability of generic treatment options.

List of Prominent Players in the Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market:
• AstraZeneca
• Boehringer Ingelheim International GmbH
• CHIESI Pharmaceutics S.p.A.
• Glaxo SmithKline plc
• Mylan N.V.
• Novartis AG
• Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Almirall
• Astellas Pharma
• Sanofi

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The increasing global prevalence of Chronic Obstructive Pulmonary Disease (COPD) is a major factor anticipated to drive the growth of the COPD therapeutics market. Rising tobacco use among younger populations and growing awareness regarding the benefits of generic medications are also contributing to market expansion. Additionally, increased healthcare expenditures in emerging economies are enhancing access to COPD treatment facilities. As public health awareness continues to improve in developing and underdeveloped regions, further growth in market demand is expected.

Challenges:
COPD is a chronic condition that typically requires prolonged medical management and specialized care, both of which involve significant costs. Many patients with COPD also suffer from additional comorbidities, further increasing the overall burden on healthcare systems. In lower-income regions, the high cost of treatment combined with limited insurance coverage can severely restrict patient access to necessary therapies. These financial barriers often lead to underdiagnosis and undertreatment, adversely affecting patient outcomes and overall quality of life.

Regional Trends:
North America is expected to hold a substantial share of the global COPD clinical trials market and is projected to register a strong compound annual growth rate (CAGR) in the coming years. This growth is supported by the region's advanced healthcare infrastructure, the presence of leading pharmaceutical companies, and a favorable regulatory framework. In the United States alone, COPD is a leading cause of morbidity and mortality, affecting approximately 16 million individuals. The high disease prevalence is driving significant demand for effective COPD treatments. Furthermore, North America's extensive network of hospitals, clinics, and pharmacies facilitates the diagnosis, treatment, and management of COPD, thereby reinforcing the region's market leadership.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2311

Recent Developments:
• In March 2023, A Phase 3 clinical trial for chronic obstructive pulmonary disease was successfully concluded by Sanofi and Regeneron with their anti-inflammatory medication. This accomplishment presents Dupixent, the medication, with the chance to become the inaugural biologic therapy to obtain authorization for the condition.
• In April 2022, GlaxoSmithKline Pharmaceuticals introduced Trelegy Ellipta for people with COPD. Trelegy Ellipta is India's first once-daily single-inhaler triple treatment (SITT) for COPD patients.

Segmentation of Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market-
By Drug Class -
• Bronchodilators
• Combination
• Corticosteroids
• Phosphodiesterase
By Type
• Chronic Bronchitis
• Emphysema
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/chronic-obstructive-pulmonary-disease-copd-clinical-trials-market/2311

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.